SIGN UP

CRISPR CEO Samarth Kulkarni and Vertex CEO Reshma Kewalramani

March 27, 2023 11:18 AM EDT

Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality

Paul Schloesser

Associate Editor

Vertex is paying nine figures to get its hands on CRISPR Therapeutics’ gene editing technology in a bid to make a third approach for type …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

sponsored

Are programs with compounded GLP-1s safe for your population?